Patients & Caregivers
FDA Accepts Resubmission of Teva's Huntington Disease Drug
Teva Pharmaceutical Industries announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) to treat chorea associated with Huntington disease (HD).
Teva's Tardive Dyskinesia Treatment Shows Positive Results in Phase 3 Trial
Teva Pharmaceutical's treatment for Tardive Dyskinesia (TD) showed a statistically significant results in its Phase 3 trial.
Monoclonal Antibody Being Tested for Huntington's Disease
VX15, a monoclonal antibody towards semaphorin 4D, is in a phase 2 clinical trial for the treatment of Huntington's disease. The antibody has also been given orphan drug designation by the FDA.
Teva Gets a Complete Response Letter for Huntington Disease Drug
SD-809 and Huntington's Disease
Samuel Franks, MD of Beth Israel Deaconess medical Center discusses the efficacy of SD-809 to treat chorea and dystonia in patients with Huntington's disease.
Spotlight on Huntington's Disease Society of America
The Huntington's Disease Society of America (HDSA) is the nation's leading nonprofit agency dedicated to serve those with Huntington's disease (HD).
Phase 2/3 Huntington's Disease Study Fails to Meet Primary Endpoint
Company to Continue Talking With FDA and EMA To Hopefully Design a Confirmatory Study.
The Genetics of Huntington's Disease is More Than the Huntingtin Gene
A DNA repair gene may, ironically, be associated with the damage that occurs on Huntington's disease.
New Huntington's Disease Natural History Study Will Help in Designing Future Clinical Trials
May is Huntington's Disease Awareness Month
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.